PCOS Diagnostic Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Test Type (Pelvic Exam, Blood Test, Transvaginal Ultrasound), By End User (Hospitals & Clinics, Fertility Clinics, Others), By Region & Competition, 2020-2030F

Market Overview

Global PCOS Diagnostic Market was valued at USD 4.76 billion in 2024 and is expected to reach USD 6.91 billion by 2030 with a CAGR of 6.54% during the forecast period. The global PCOS diagnostic market is gaining significant attention due to the increasing prevalence of polycystic ovary syndrome (PCOS) among women of reproductive age. PCOS is a complex endocrine disorder that affects hormonal levels, metabolism, and overall reproductive health, often leading to complications such as infertility, obesity, and diabetes.

A 2024 study published by ScienceDirect reveals that North America spends nearly USD 4 billion on polycystic ovary syndrome (PCOS) and related conditions. Menstrual irregularities were observed in 22.8% of patients. The Alberta Women's Health Foundation's February 2023 report estimates that around 1.4 million women in Canada may have PCOS. Companies are investing in research to develop new treatment options and address the rising prevalence of PCOS. The growing awareness around early diagnosis and treatment of PCOS has led to a higher demand for diagnostic services and tools. Diagnostic methods for PCOS typically involve a combination of physical examination, medical history analysis, hormonal blood tests, and imaging techniques like pelvic ultrasound.

As healthcare systems advance and access to diagnostic technologies improves, more women are seeking early diagnosis and intervention. Healthcare professionals are becoming more adept at identifying the broad spectrum of PCOS symptoms, which can vary widely from patient to patient. For instance, according to the World Health Organization (WHO) report published in June 2023, polycystic ovary syndrome (PCOS) affects 8-13% of women of reproductive age, with approximately 70% of those affected remaining undiagnosed worldwide. This highlights the need for improved awareness and diagnostic efforts.

Key Market Drivers

Increasing Prevalence of PCOS

The increasing prevalence of polycystic ovary syndrome (PCOS) is one of the primary drivers fueling the growth of the global PCOS diagnostic market. For instance, the World Health Organization (WHO) notes that women with a family history of type 2 diabetes are at higher risk of developing polycystic ovary syndrome (PCOS). Also,the Centers for Disease Control and Prevention (CDC) states that PCOS sufferers often experience insulin resistance, which can lead to type 2 diabetes. The rising prevalence of these chronic conditions is expected to drive growth in the treatment market.

Also, Obesity is another factor contributing to polycystic ovary syndrome (PCOS). The World Health Organization (WHO) reported that 2.5 billion adults were overweight in 2022, with 44% being women. Those affected by obesity are more likely to develop PCOS, as weight gain exacerbates the condition, according to the endocrine center. The growing prevalence of obesity and PCOS cases is driving market growth. As a hormonal disorder affecting a significant portion of women in their reproductive years, PCOS is now more frequently recognized as a major public health concern. Contributing factors such as sedentary lifestyles, poor dietary habits, obesity, and genetic predisposition have led to a marked rise in PCOS cases worldwide. This surge in prevalence directly translates into a higher demand for timely and accurate diagnostic tools and services, propelling the market forward.

PCOS often presents with a range of symptoms—including irregular menstrual cycles, excessive hair growth, acne, and infertility—which vary widely among individuals. This variation complicates diagnosis and has historically led to underdiagnosis or misdiagnosis. However, with more women experiencing symptoms and seeking medical attention, healthcare providers are increasingly emphasizing early and comprehensive diagnostic evaluations. This shift is expanding the market for diagnostic tests such as hormonal assays, glucose tolerance tests, and pelvic ultrasounds.

The growing recognition of the long-term health risks associated with untreated PCOS—including type 2 diabetes, cardiovascular disease, and endometrial cancer—is pushing both patients and providers to prioritize early detection. As awareness spreads, more women are undergoing screening, and more healthcare systems are incorporating PCOS assessments into routine care for at-risk individuals.

The global rise in PCOS cases, coupled with growing awareness and the need for early intervention, is thus creating a sustained demand for diagnostic solutions. This trend is expected to continue, particularly as developing nations improve access to women's health services. As a result, the PCOS diagnostic market is poised for steady expansion, with the increasing disease burden serving as a key catalyst for its growth..

Growing Awareness and Early Diagnosis

Growing awareness and the increasing emphasis on early diagnosis are pivotal factors contributing to the growth of the global PCOS diagnostic market. In recent years, both healthcare providers and the general public have become more aware of polycystic ovary syndrome (PCOS) and its potential long-term health consequences. As knowledge of the disorder has expanded, so too has the recognition of the importance of early diagnosis for better management and treatment outcomes. This growing awareness has led to a surge in demand for diagnostic services, as more women seek to identify PCOS at earlier stages, when interventions can be more effective.

One of the significant ways in which awareness has grown is through educational campaigns and outreach by healthcare organizations, including advocacy groups and women’s health initiatives. These campaigns have highlighted the prevalence of PCOS and its association with infertility, metabolic issues, and increased risk of other chronic conditions such as diabetes and heart disease. As a result, women are increasingly recognizing the signs and symptoms of PCOS, prompting them to seek medical advice and diagnostic tests.

The healthcare professionals have become more adept at diagnosing PCOS, thanks to enhanced training and the availability of advanced diagnostic tools. Early diagnosis not only helps in managing symptoms such as menstrual irregularities, acne, and excessive hair growth but also allows for preventive measures to mitigate the risk of associated conditions like type 2 diabetes. As a result, the demand for diagnostic procedures, such as hormone level testing, ultrasound scans, and metabolic assessments, has risen steadily.

This heightened focus on early diagnosis, driven by both improved awareness and the increasing availability of diagnostic technology, is a significant catalyst for market growth. As more women opt for proactive healthcare, the demand for accurate and timely PCOS diagnostic solutions is expected to continue expanding in the coming years.

Demand for Point-of-Care Testing

The growing demand for point-of-care (POC) testing is playing a crucial role in driving the expansion of the global PCOS diagnostic market. Point-of-care testing refers to medical diagnostic tests that are conducted outside traditional laboratory settings, typically at the patient’s location, such as in clinics, pharmacies, or even at home. This shift toward more accessible, real-time diagnostic solutions has significantly enhanced the speed and convenience of detecting conditions like polycystic ovary syndrome (PCOS). As patients and healthcare providers seek more immediate results and streamlined healthcare experiences, the demand for POC testing solutions has surged, contributing to the growth of the PCOS diagnostic market.

The key advantage of POC testing is its ability to deliver quick results, enabling immediate decision-making. For PCOS, where early detection is essential for managing symptoms and preventing long-term complications, the ability to rapidly assess key factors like hormonal imbalances, glucose levels, and other metabolic indicators is highly valuable. This has made POC diagnostic tools highly appealing to women seeking efficient ways to monitor their reproductive health. With faster results, patients can start treatment or management plans promptly, minimizing the potential for complications like infertility or diabetes.

In addition, the growing trend towards home healthcare and telemedicine is further fueling the adoption of POC testing. Women who may have limited access to healthcare facilities or those who prefer convenience are turning to home-based diagnostic solutions for PCOS. Over-the-counter hormone level tests, glucose monitors, and even ovulation kits have become increasingly popular, allowing individuals to monitor their condition without frequent visits to a clinic.The rise in demand for point-of-care testing not only improves patient outcomes but also offers a cost-effective and patient-friendly alternative to traditional diagnostic methods. As this demand continues to increase, it plays a key role in driving the growth of the PCOS diagnostic market, ensuring broader access and better management of the condition globally.

Download Free Sample Report

Key Market Challenges

Underdiagnosis and Misdiagnosis

Underdiagnosis and misdiagnosis of polycystic ovary syndrome (PCOS) represent significant challenges in the global PCOS diagnostic market, directly influencing its growth. PCOS is a complex condition with a wide array of symptoms that vary greatly between individuals, making it difficult to identify, especially in the early stages. Symptoms such as irregular menstrual cycles, acne, and excessive hair growth are often misunderstood or attributed to other, more common conditions. As a result, many women go undiagnosed for years, which not only delays proper treatment but also exacerbates the risk of long-term health complications, such as infertility, type 2 diabetes, and cardiovascular diseases.

This underdiagnosis is a key barrier to market growth, as a significant portion of the population may not seek or receive the necessary diagnostic tests. Misdiagnosis further complicates the issue. The overlapping symptoms of PCOS with other disorders, like thyroid dysfunction or stress-related conditions, can lead to incorrect treatments, which ultimately hinder proper disease management. Without a timely and accurate diagnosis, patients may not benefit from early interventions, leading to the persistence of symptoms and increased healthcare costs in the long run.

As awareness of PCOS increases, however, more women are seeking proper diagnosis, prompting growth in the diagnostic market. For this growth to be sustained, it is essential that healthcare professionals are better equipped to recognize the signs of PCOS and that women have access to reliable and accurate diagnostic tests. Addressing underdiagnosis and misdiagnosis will lead to more women seeking early diagnosis, thereby driving demand for PCOS diagnostic tools and services, ultimately expanding the market.

Lack of Standardized Diagnostic Criteria

The lack of standardized diagnostic criteria for polycystic ovary syndrome (PCOS) poses a significant challenge to the global PCOS diagnostic market, potentially hindering its growth. Currently, several diagnostic criteria exist for PCOS, with the Rotterdam Criteria being the most widely accepted, but these guidelines are not universally followed across all regions. Variations in diagnostic protocols, such as differences in the hormonal assays used or the thresholds for ovarian cysts on ultrasound, can lead to inconsistent diagnoses. This lack of uniformity can create confusion among healthcare providers and patients, delaying the recognition of the condition and affecting the timely initiation of treatment.

The inconsistent diagnostic criteria mean that women may receive differing levels of care depending on where they live or which healthcare provider they consult. In regions where healthcare professionals are less familiar with the latest diagnostic guidelines, PCOS may go undiagnosed or misdiagnosed, limiting the market’s potential. This inconsistency also affects the development and adoption of diagnostic tools. Manufacturers of PCOS diagnostic products face challenges in creating universally accepted tests that cater to varying criteria, leading to difficulties in achieving widespread market acceptance. A standardized diagnostic framework would not only streamline the diagnosis process but also increase the reliability of diagnostic tools, driving confidence in their use among healthcare providers and patients. Establishing clear, uniform criteria would ultimately expand the global market for PCOS diagnostics by ensuring that more women are accurately diagnosed and treated. As the need for consistent and standardized testing grows, the market for reliable diagnostic solutions is expected to grow accordingly.

Key Market Trends

Focus on Early Detection and Intervention

The increasing focus on early detection and intervention is a key trend driving the growth of the global PCOS diagnostic market. Early diagnosis of polycystic ovary syndrome (PCOS) is crucial for managing symptoms effectively and preventing the long-term health complications often associated with the condition, such as infertility, diabetes, and cardiovascular diseases. As awareness of PCOS has risen, healthcare providers and patients alike are prioritizing early screening and diagnosis, which is significantly expanding the demand for diagnostic tools.

Timely intervention is essential for addressing the hormonal imbalances and metabolic issues common in PCOS, and this trend has spurred the development of more advanced diagnostic tests. These tests, which may include hormonal assays, metabolic screening, and imaging technologies like ultrasounds, are increasingly being utilized to detect the condition before it leads to more severe health issues. Early detection enables healthcare providers to recommend lifestyle changes, medications, or fertility treatments in a timely manner, improving the overall quality of life for patients. The rise in preventive healthcare and patient empowerment is contributing to this trend. With more women seeking proactive management of their health, there is a growing demand for diagnostic solutions that allow for quicker and more accurate assessments. As healthcare systems integrate early PCOS screening into routine checkups, especially for women at risk, the market for PCOS diagnostics continues to expand. Ultimately, the focus on early detection and intervention not only leads to better patient outcomes but also plays a significant role in driving the growth of the global PCOS diagnostic market.

Shift Towards Multimodal Diagnostic Approaches

The shift towards multimodal diagnostic approaches is a significant trend propelling the growth of the global PCOS diagnostic market. As polycystic ovary syndrome (PCOS) presents a wide range of symptoms that can overlap with other conditions, relying on a single diagnostic tool can often lead to inaccurate or incomplete results. To address this, healthcare providers are increasingly adopting multimodal diagnostic strategies that combine various testing methods to improve diagnostic accuracy and provide a more comprehensive understanding of the condition.

Multimodal approaches typically involve a combination of clinical evaluation, hormone level assessments, imaging techniques such as pelvic ultrasounds, and metabolic screenings. For instance, ultrasound imaging is used to identify ovarian cysts, while blood tests measure hormone imbalances like elevated testosterone levels, a common marker of PCOS. Together, these diagnostic methods can help clinicians make more accurate and timely diagnoses, which is critical for effective management of PCOS.

The growing trend towards multimodal diagnostic approaches is also being driven by advancements in technology, making these combined testing methods more accessible and affordable. This shift enables healthcare professionals to take a holistic view of a patient’s health, leading to more personalized treatment plans. As the demand for accurate, early, and comprehensive diagnostics increases, the market for multimodal diagnostic tools is expanding. This trend not only improves diagnostic outcomes but also enhances patient satisfaction, as women are more likely to seek comprehensive testing when they understand that it leads to better, faster diagnoses. The continued adoption of multimodal approaches is expected to fuel further growth in the PCOS diagnostic market, particularly as healthcare systems and technologies evolve.

Segmental Insights

Test Type Insights

Based on test type, Transvaginal ultrasound is emerging as the fastest growing segment in the PCOS diagnostic market, driven by its non-invasive nature, high accuracy, and ability to clearly visualize ovarian cysts—a key indicator of the condition. This method allows quick identification of cysts and assessment of ovarian size, providing critical confirmation in cases where symptoms overlap with other disorders. While pelvic exams and blood tests remain important complementary tools, they often lack the comprehensive diagnostic clarity that ultrasound offers. The ability of transvaginal ultrasound to deliver immediate, reliable, and detailed insights positions it as the most rapidly expanding diagnostic approach for PCOS..

Download Free Sample Report

Regional Insights

North America dominated the global PCOS diagnostic market due to several key factors, including advanced healthcare infrastructure, high awareness, and a strong focus on early diagnosis. The region benefits from well-established healthcare systems, which ensure access to cutting-edge diagnostic tools and technologies such as transvaginal ultrasound, hormone testing, and metabolic screenings. These advanced diagnostic methods are widely available in North America, making it easier for women to get accurate and timely diagnoses.

The region boasts a high level of awareness about PCOS, both among healthcare providers and the general public. Public health campaigns, educational programs, and increased media coverage have all contributed to a better understanding of the condition, leading more women to seek medical advice and diagnostic testing. Early diagnosis is prioritized, as healthcare systems emphasize preventive care and early intervention to manage symptoms and avoid complications like infertility, diabetes, and cardiovascular disease. North America has a relatively high incidence of PCOS, which drives demand for diagnostic services. With rising healthcare expenditure, a focus on women’s health, and a growing awareness of PCOS's long-term effects, North America is poised to remain the leading market for PCOS diagnostics. These factors collectively make North America the dominant region in the global PCOS diagnostic market.

Recent Developments

• In 2024, Roche introduced a new CE-marked blood test aimed at simplifying the diagnosis of polycystic ovary syndrome (PCOS). This innovative test offers a more streamlined and accessible diagnostic option, enabling quicker and more accurate detection of PCOS. By focusing on key biomarkers, the test helps healthcare providers diagnose the condition efficiently, supporting early intervention and better management of PCOS symptoms for women worldwide.
• In 2024, Roche received CE mark approval for its Elecsys anti-müllerian hormone plus immunoassay, offering an alternative to transvaginal ultrasound for diagnosing polycystic ovary syndrome (PCOS). This diagnostic tool provides a less invasive option, enabling healthcare providers to detect PCOS more efficiently and accurately, enhancing patient care and facilitating early intervention.
• In 2024, a simplified PCOS diagnostic process enables women to receive quicker, more accurate diagnoses and timely treatments. This streamlined approach enhances access to care, promoting early intervention and better management of PCOS, ultimately improving women's health outcomes by addressing symptoms and preventing long-term complications.
• According to a 2024 article, PCOS symptoms remain challenging for doctors to diagnose and treat. Despite being identified 90 years ago, there are still no FDA-approved drugs for this complex hormonal disorder, making diagnosis and management difficult for healthcare providers and patients alike.

Key Maaket Players

• Siemens Healthineers AG
• GE Healthcare
• Mindray Medical International Limited
• Esaote S.p.A
• Telemed Medical Systems
• Shantou Institute of Ultrasonic Instruments Co., Ltd. (SIUI)
• BK Medical
• Alpinion Medical Systems
• Mindray ZONARE Medical Systems
• Xianfeng Ultrasound Medical

Report Scope:

In this report, the Global PCOS Diagnostic Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• PCOS Diagnostic Market, By Test Type:

o   Pelvic Exam

o   Blood Test

o   Transvaginal Ultrasound

• PCOS Diagnostic Market, By End User:

o   Hospitals & Clinics

o   Fertility Clinics

o   Others   

• PCOS Diagnostic Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia-Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global PCOS Diagnostic Market.

Available Customizations:

Global PCOS Diagnostic Market report with the given market data, TechSci Research, offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global PCOS Diagnostic Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]